MARKET

MEIP

MEIP

MEI Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.120
+0.100
+3.31%
After Hours: 3.210 +0.09 +2.88% 16:57 09/25 EDT
OPEN
2.980
PREV CLOSE
3.020
HIGH
3.170
LOW
2.980
VOLUME
513.95K
TURNOVER
--
52 WEEK HIGH
4.459
52 WEEK LOW
0.7200
MARKET CAP
351.07M
P/E (TTM)
-5.7607
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
MEI Pharma (MEIP) Presents At H.C. Wainwright 22nd Annual Global Investment Conference - Slideshow
The following slide deck was published by MEI Pharma, Inc. in conjunction with this event.
Seekingalpha · 09/17 18:33
MEI Pharma Appoints Brian T. Powl As Senior Vice President, Marketing
MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the appointment of Brian T. Powl as senior vice president, marketing, a new role that will report to David Urso, chief operating officer and general counsel
PR Newswire · 09/15 12:00
Earnings Release: Here's Why Analysts Cut Their MEI Pharma, Inc. (NASDAQ:MEIP) Price Target To US$9.50
It's shaping up to be a tough period for MEI Pharma, Inc. (NASDAQ:MEIP), which a week ago released some disappointing...
Simply Wall St. · 09/13 13:35
Checkpoint Therapeutics, Nano-X Imaging leads healthcare gainers, Evofem Biosciences, Satsuma Pharmaceuticals among major losers
Gainers: Checkpoint Therapeutics (CKPT) +29%, Nano-X Imaging (NNOX) +21%, Biofrontera AG (BFRA) +20%, Zymeworks (ZYME) +14%, MEI Pharma (MEIP) +12%.Losers: Evofem Biosciences (EVFM) -20%, Satsuma Pharmaceuticals (STSA) -11%, Corbus Pharmaceuticals Holdings (CRBP) -10%, Savara (SVRA) -9%, BiondVax Pharmaceuticals (BVXV) -8%.
Seekingalpha · 09/11 15:05
MEI Pharma Reports Fiscal Year 2020 Results and Operational Highlights
MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its fiscal year ended June 30, 2020.
PR Newswire · 09/09 21:05
MEI Pharma EPS misses by $0.36, misses on revenue
MEI Pharma (MEIP): FY GAAP EPS of -$0.51 misses by $0.36.Revenue of $28.91M (+487.6% Y/Y) misses by $10.09M.Shares -2.24%.Press Release
Seekingalpha · 09/09 20:08
MEI Pharma, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / September 9, 2020/ MEI Pharma, Inc.
ACCESSWIRE · 09/09 19:00
The Week Ahead In Biotech: Focus On Mallinckrodt FDA Decision, Conference Presentations
After remaining steady in the first three sessions of the week ended Sept. 4, biotech stocks pulled back along with the broader market in a tech-induced sell-off.
Benzinga · 09/06 17:25
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MEIP. Analyze the recent business situations of MEI Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MEIP stock price target is 9.39 with a high estimate of 13.00 and a low estimate of 5.50.
EPS
Institutional Holdings
Institutions: 130
Institutional Holdings: 75.10M
% Owned: 66.74%
Shares Outstanding: 112.52M
TypeInstitutionsShares
Increased
41
12.78M
New
43
3.33M
Decreased
18
13.91M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.03%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chief Executive Officer/President/Director
Daniel Gold
Chief Financial Officer/Secretary
Brian Drazba
Chief Operating Officer/General Counsel
David Urso
Senior Vice President/Director of Marketing
Brian Powl
Other
Robert Mass
Director
Cheryl Cohen
Independent Director
Charles Baltic
Independent Director
Kevan Clemens
Independent Director
Frederick Driscoll
Independent Director
Nicholas Glover
Independent Director
Tamar Howson
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MEIP
MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company's portfolio of clinical drug candidates includes Pracinostat, ME-344 and ME-401. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. ME-401 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of MEI Pharma Inc stock information, including NASDAQ:MEIP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MEIP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MEIP stock methods without spending real money on the virtual paper trading platform.